This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our Cookie Policy and Privacy Policy.

close

Continue

Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Profile

Anna Persson is a Senior Principal Data Scientist with the Data Analytics division of Sartorius-Stedim Biotech. In her work with Sartorius and Umetrics Software she customizes solutions of advanced data analytics for customers in the pharmaceutical and biopharmaceutical industry, as well as other areas. Anna has a Master’s degree in Engineering Chemistry with a focus on chemometrics from Umea University in Sweden. She specializes in process chemometrics and is based in New York City.

Agenda Sessions

How to Support and Improve CAR-T Process Performance Through Advanced Data Analytics

Often autologous cellular therapies, and CAR-T in particular, present unique challenges in manufacturing due to the variability of the starting material and the unique nature of each batch. So far most manufacturing processes employ a fairly rigid approach that does not compensate for the unique characteristics of the starting material. Drawing on years of experience applying advanced analytics to manufacturing in the biotechnology space, we propose the use of the same off the shelf tools to improve autologous therapies. These tools allow categorization of starting materials, process optimization, flexibility in manufacturing, enhanced real-time fault detection and prediction of critical quality attributes (CQA’s). An overview of benefits, necessary pre-requisites and implementation of advanced analytics in manufacturing safe and effective therapies will be provided.